Investigation of preventive effects of magnesium oxide for panitumumab-related hypomagnesemia

• Autores: Rei Tanaka, Hiroshi Ishikawa, Junya Sato, Michihiro Shino, Takao Aoyama, Kentaro Yamazaki
• Localización: European journal of clinical pharmacy: atención farmacéutica, ISSN 2385-409X, Vol. 21, Nº. 4, 2019, págs. 187-192
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Hypomagnesemia is an adverse event that frequently occurs as a result of anti-EGFR antibodies therapy such as panitumumab. In order to enable the complete implementation of treatment, it is very important to prevent hypomagnesemia. While the use of oral magnesium agents, which are safer and simpler to administer than injections, is ideal for preventing this condition, the effects of such agents have not been sufficiently reported. Therefore, we investigated the preventive effects of the oral administration of magnesium oxide for panitumumab-related hypomagnesemia. We divided our subjects, comprising 86 cases of wild-type KRAS unresectable colorectal cancer administered panitumumab at the Shizuoka Cancer Center between April 2010 and March 2016, into a magnesium oxide concomitant group (con-comitant group) and a non-concomitant group. We then retrospectively investigated hypomagnesemia incidence and severity (CTCAE ver. 4.0) within six weeks from the start of panitumumab administration, as well as over the entire treatment period. The 86 subjects comprised 24 subjects in the concomitant group and 62 subjects in the non-concomitant group. Hypomagnesemia incidence within six weeks from the start of panitumumab administration was 16.7% in the concomitant group and 41.9% in the non-concomitant group (p = 0.042), while severity (Grl/2/3/4) was 2/2/0/0 patients in the concomitant group and 23/3/0/0 patients in the non-con-comitant group (p = 0.043), both indicating significant differences. Over the entire treatment period, however, incidence was 41.7% in the concomitant group and 51.6% in the non-concomitant group (p = 0.475), while severity (Grl/2/3/4) was 7/3/0/0 patients in the concomitant group and 25/6/1/0 patients in the non-con-comitant group (p = 0.505), indicating no significant differences. The concomitant use of magnesium oxide might reduce the incidence and severity of panitumumab-related hypomagnesemia within six weeks after starting administration, although no long-term preventive effects were confirmed. © 2019 Rasgo Editorial S.A.. All rights reserved.